Domain Associates and Apax Partners each invested $9 million into the specialty pharmaceutical company. New Enterprise Associates invested $8 million, and ESP Pharma’s management also invested $2 million.

Partner Michael Sanders led the deal from Crosby’s Century City office. He said the deal went through rather quickly, starting with the negotiating of a term sheet in mid-March and closure of the deal by the end of May.

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]